Nurix Therapeutics, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs that modulate protein degradation and cellular signaling pathways, primarily targeting cancer and autoimmune diseases through its DELigase drug discovery platform. Its programs focus on degrading or inhibiting disease-causing proteins, including targets like BTK and CBL-B, often in collaboration with partners such as Gilead and Sanofi.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Ring ChristineChief Legal Officer | Sell | $245K | 9,527at $25.74 | Nov 2, 2026 |
| van Houte HansChief Financial Officer | Sell | $24K | 1,469at $16.20 | Nov 4, 2026 |
| van Houte HansChief Financial Officer | Sell | $51K | 3,300at $15.38 | Nov 4, 2026 |
| Ring ChristineChief Legal Officer | Sell | $158K | 6,113at $25.83 | Nov 3, 2026 |
| Ring ChristineChief Legal Officer | Sell | $29K | 1,075at $26.76 | Nov 2, 2026 |
| Hansen GwennChief Scientific Officer | Sell | $104K | 3,957at $26.28 | Oct 30, 2026 |
| Ring ChristineChief Legal Officer | Sell | $104K | 3,957at $26.28 | Oct 30, 2026 |
| van Houte HansChief Financial Officer | Sell | $74K | 2,834at $26.28 | Oct 30, 2026 |
| Hansen GwennChief Scientific Officer | Sell | $39K | 1,452at $26.80 | Nov 2, 2026 |
| Hansen GwennChief Scientific Officer | Sell | $36K | 1,452at $25.00 | Oct 15, 2026 |
| GREGORY JULIA PDirector | Sell | $529K | 22,583at $23.40 | Oct 14, 2026 |
| Ring ChristineChief Legal Officer | Sell | $11K | 400at $26.64 | Sep 2, 2026 |
| Ring ChristineChief Legal Officer | Sell | $138K | 5,387at $25.69 | Sep 2, 2026 |
| Hansen GwennChief Scientific Officer | Sell | $109K | 4,356at $25.00 | Aug 5, 2026 |
| van Houte HansChief Financial Officer | Sell | $43K | 1,794at $23.89 | Aug 4, 2026 |
| van Houte HansChief Financial Officer | Sell | $73K | 2,967at $24.65 | Aug 4, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable NRIX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.